Overall Response Rate
4 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE (NCT01291667) | Shanghai CP Guojian Pharmaceutical Co., Ltd. | 2009-05-01 |
Track Overall Response Rate automatically
Every clearance here is in the API, with alerts when new ones post.